Filing Flows › Theriva Biologics (TOVX) › Stock forecast & fair value
Theriva Biologics (TOVX) stock forecast and price target
Theriva Biologics (TOVX) trades at $0.17. One analyst's price target is $4.00 (24×).
Theriva Biologics' latest quarter
Theriva Biologics, Q1 2026: revenue $300K, operating margin -709.0%, net loss $2.0M, operating cash flow −$2.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for TOVX stock?
One analyst's 12-month target is $4.00, 24× from $0.17. The average rating is strong buy.
Does Theriva Biologics usually beat earnings estimates?
It beat the consensus EPS estimate in 0% of the quarters on record.
Is TOVX stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.